Can we reach suitable $^{161}$Tb purity for medical applications using the$^{160}$Gd(d,n) reaction?

International audienceTerbium is a chemical element that has several radioactive isotopes with suitable physical characteristics to be used in medical applications either for imaging or for therapy. This makes terbium a promising element to implement the theranostic approach. For therapeutic applications, 161Tb (T1/2 = 6.89 d) is suitable for targeted β-therapy. The main production route is through neutron capture reaction in nuclear reactors. In this work, we explored an alternative production route, the 160Gd(d,n)161Tb reaction. We have measured its production cross-section as well as those of possible co-produced contaminants, with a special focus on 160Tb (T1/2 = 72.3 d). To achieve this, cross-section measurements were made from natural gadolinium target. Production yields of 10.3 MBq/μA/h for the 161Tb and 1.5 MBq/μA/h for the 160Tb were obtained at 20 MeV. A161Tb radionuclidic purity of 86% was achieved over the 8 MeV–20 MeV energy range. The co-production of other terbium isotopes limits the interest of using higher energies. Based on the limited purity of 161Tb using the 160Gd(d,n)161Tb reaction, we conclude that it is not a production route suitable for medical applications. Although, this may be reconsidered when mass separation technique with high efficiency will be available. •161Tb is well suited to implement the theranostic approach (Tb family).•Study of an alternative 161Tb production route using accelerators.•Cross section measurements using the stacked foils technique and gamma spectrometry.•Production yield calculations for 161Tb and 160Tb and comparison to literature.•Optimisation of 161Tb purity knowing the co-production of 160Tb contaminant